Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma.
Chiara ChiavelliMalvina PrapaGiulia RovestiMarco SilingardiGiovanni NeriGiuseppe PuglieseLucia TruduMassimiliano Dall'OraGiulia GolinelliGiulia GrisendiJonathan VinetMarco BestagnoCarlotta SpanoRoberto Vito PapapietroRoberta DepenniKatia Di EmidioAnna PasettoDaniela Nascimento SilvaAlberto FelettiSilvia BerlucchiCorrado IaccarinoGiacomo PavesiMassimo DominiciPublished in: NPJ precision oncology (2024)
Glioblastoma (GBM) remains a deadly tumor. Treatment with chemo-radiotherapy and corticosteroids is known to impair the functionality of lymphocytes, potentially compromising the development of autologous CAR T cell therapies. We here generated pre-clinical investigations of autologous anti-GD2 CAR T cells tested against 2D and 3D models of GBM primary cells. We detected a robust antitumor effect, highlighting the feasibility of developing an autologous anti-GD2 CAR T cell-based therapy for GBM patients.
Keyphrases
- induced apoptosis
- bone marrow
- cell therapy
- platelet rich plasma
- cell cycle arrest
- end stage renal disease
- endothelial cells
- early stage
- chronic kidney disease
- newly diagnosed
- locally advanced
- prognostic factors
- endoplasmic reticulum stress
- stem cells
- photodynamic therapy
- cell death
- oxidative stress
- mesenchymal stem cells
- signaling pathway
- drug delivery
- rectal cancer
- radiation induced
- combination therapy
- patient reported outcomes